[Effect of taspine derivatives on human liver cancer SMMC7721]
Yan-min Zhang1, Nan Wang, Bing-ling Dai
1School of Medcine, Xi'an Jiaotong University, Xi'an 710061, China. zhang2008@mail.xjtu.edu.cn
Objective:
To analyse the inhibition effect of taspine derivatives on human Liver cancer SMMC7721 cell and its mechanism.
Methods:
The effects of five taspine derivatives on SMMC7721 cell growth were determined by MTT. The flow cytometry was used to determine the cell cycle. The effects of Tas-D1 on the EGF and VEGF in SMMC7721 cell were determined by ELISA. The mRNA level of EGF and VEGF in SMMC7721 cell was determined by RT-PCR.
Results:
The MTT assay demonstrated that the taspine derivative Tas-D1 significantly inhibited the growth of SMMC7721 cell in a dose-dependent manner. Cell was stopped at S phase by Tas-D1. Tas-D1 inhibited the expression of EGF and VEGF and their mRNA in a dose-dependent manner (P<0.05).
Conclusions:
The taspine derivative Tas-D1 can inhibit the growth of human Liver cancer SMMC7721 cell and change cell cycle, which may be related to the inhibition of EGF and VEGF expression.
Insights
The taspine derivative Tas-D1 effectively inhibits human liver cancer SMMC7721 cell growth by altering the cell cycle. This inhibition may be linked to reduced expression of epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF).
Area of Science:
- Pharmacology
- Molecular Biology
- Cancer Research
Context:
- Hepatocellular carcinoma (HCC) remains a significant global health challenge.
- Developing novel therapeutic agents for liver cancer is crucial.
- Taspine derivatives represent a potential class of anticancer compounds.
Purpose:
- To investigate the inhibitory effects of taspine derivatives on human liver cancer SMMC7721 cells.
- To elucidate the underlying mechanisms of action, including cell cycle regulation and growth factor expression.
Summary:
- Five taspine derivatives were screened for their effects on SMMC7721 cell growth using MTT assays.
- The most potent derivative, Tas-D1, was found to inhibit cell proliferation in a dose-dependent manner and induce S-phase arrest.
- Tas-D1 significantly reduced the expression of epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF) at both protein and mRNA levels.
Impact:
- Identifies Tas-D1 as a promising candidate for further development in liver cancer therapy.
- Provides mechanistic insights into how taspine derivatives exert their anticancer effects.
- Suggests a potential therapeutic strategy targeting EGF and VEGF pathways in liver cancer.
